Baiji Shenzhou announced an exclusive licensing agreement for the new coronavirus and antibodies developed by Danshu Bio.
Thyme Bio announces financial results and company progress for the first half of 2020.
The first in China! Junshi Bio-Anti-PD-1 Therapy Ripley Monoanti (Toyi ®) has been recognized
There has been new progress in phase III clinical trials of the Vantai Bio-Nine-Price Vaccine (E. coli).
Immunity: Allergic reactions help fight bacterial infections.
Xinda Bio IBI112 Phase I clinical study completed the first subject's drug use.
Junshi Bio Semi-Annual Report: Revenue of 575 million yuan, up 86% YoY
Regent Bio has reached a strategic partnership with Jess Inda to conduct clinical studies on PD-1 single-anti-joint ERK inhibitor JSI-1187.
Domestic new crown vaccine: hundreds of thousands of people have been urgently vaccinated, zero infection, no case of obvious adverse reactions.
Tongli Bio completed tens of millions of yuan of financing to promote the clinical development
Xinda Bio announced that Adamo single anti-injection sulyxin ® officially approved for listing in China.
Focus on improving the development of new drugs! Qingpu Bio successfully obtained nearly 50 million yuan pre-A round financing.
Russian "bio-detectors" can detect new coronavirus in the air.
Artificial bio-carbon sequestration pathway CETCH cycle technology.
Groundwater bio-rehabilitation engineering technology.
Bio-hacking will be strictly regulated.
First-line immunotherapy for lung cancer! Cinda Bio/Lilly Daboshu ® treatment of non-scaly non
Kangfang Bio PD-1/CTLA-4 dual resistance is eligible for FDA fast-track approval.
Concino Bio today landed on the board to become the first "A-H" vaccine unit.
In the United States bio-similar drugs "golden age" Pfizer, Amjin will make a fortune!